Rolf Jan Rutten

Rolf Jan Rutten is the CEO of Oncosence, a company focused on targeting senescence in oncology.13 He is an experienced entrepreneur and executive in the pharmaceutical and biotechnology industry.2

Professional Background

Rutten has extensive experience in various aspects of the biotech and pharmaceutical sectors:

• Business Development: He has a strong background in this area.2
• Product Development: Rutten has played roles in product development within the industry.2
• Early Clinical Development: He has experience in this crucial phase of drug development.1

Entrepreneurial Ventures

Rolf Jan Rutten is known as a serial entrepreneur.3 Some of his notable ventures include:

• Audion Therapeutics: Founder and CEO12
• ThromboDX: Founder (later sold to Illumina)1
• DyblyAG: Founder1

Role at Oncosence

As the CEO of Oncosence, Rutten is leading a company that is taking a novel approach to cancer treatment. Oncosence is unique in its focus on targeting senescence in oncology.3

Skills and Expertise

Rutten's areas of expertise include:

• Translational Strategy
• Clinical Trials
• International Management

His diverse experience makes him well-suited to lead Oncosence in its innovative approach to cancer treatment.1